What is Amplis?

Amplis is an advanced genetic™ tool to assist clinicians in prescribing decisions. It provides medication assistance for depression and commonly co-occurring conditions (e.g. heart disease, anxiety, diabetes) and leverages insights from high-quality clinical trials and blood-brain-barrier genetics. Amplis is the most advanced tool available for depression medication management.

Advanced Depression Medication Management:

Amplis provides an array of innovative approaches to depression medication management including:

  • Antidepressant guidance based off advanced blood-brain barrier and liver genetics
  • High quality clinical trials on antidepressant genetic guidance, including a Randomized Controlled Trial and Concordance Study
  • Genetic guidance for medications for conditions which commonly co-occur with depression, such as heart disease, diabetes and anxiety
  • Non-genetic guidance features will assist in managing late-life depression, polypharmacy and deprescribing issues in the elderly
  • Access to an in-depth modeling tool

The Amplis™ Report provides you with a powerful new tool to guide your prescribing decisions. With a simple cheek swab, you can get a personalized view of your patient, with guidance on which medications may be the best match for their genetic profile.


  • The Amplis™ Report is a decision support tool for clinicians, based on advanced genetic technologies. This personalized report may lessen the need for trial-and-error prescribing and reduce adverse reactions. Amplis may lessen the trial and error of medication prescribing by providing you with suggested medications and doses that are based on your patient’s genetic profile

  • Amplis™ may reduce adverse drug reactions by providing you with a risk analysis of your patient’s current drug regimen and access to a portal that will enable you to model alternative medication plans in real time


  • Depression commonly co-occurs with chronic conditions including diabetes and heart disease. Depression is associated with reduced adherence to care plans
  • The current standard of care for antidepressant treatment is trial-and-error and there is only a 50% response rate
  • Late life depression occurs in 10 – 15% of people over 65 years of age
  • 30% of older adults in the United States taking five or more drugs simultaneously, also known as polypharmacy.
  • Polypharmacy has been shown to increase risk for negative health outcomes resulting from drug-interactions, medication non-adherence, decreased functional status and geriatric syndromes (e.g. delirium and falls)


  • Bain et al (2018) Implementation of a pharmacist-led pharmacogenomics services for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). J Am Pharmaco Assoc. 58(3)
  • Bousman CA.. Singh AB.. et al (2017). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study. Pharmacogenetics and Genomics, 27.1:1.
  • Bousman CA.. Eyre HA.. et al (2019) Pharmacogenetics tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 20(1).
  • Chang DD .. Eyre HA.. et al (2018) Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. Pharmacogenomics. 19(16).
  • Gharani et al (2013) The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Medicine, 5:93.
  • Peterson K et al (2017) The Comparative Effectiveness, Harms, and Cost-effectiveness of Pharmacogenomics-Guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder. VA Evidence-based Synthesis Program. www.ncbi.nlm.nih.gov/books/NBK384610/
  • Singh AB (2015). Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clinical Psychopharmacology Neuroscience, 13.2:150.


Amplis provides best in class guidance on medication treatments with four key unique points:

  • Genetic and non-genetic guidance
  • Antidepressant guidance based off of advanced blood-brain barrier and liver genetics
  • Guidance for diverse medication classes derived from a world-leading precision medicine study
  • Access to a dynamic portal




Antidepressant Guidance

Test Description1,2:

AMPLIS is best in class pharmacogenetic guidance for Anti-Depressant selection. RCT1 and concordance2 studies both indicate Amplis may greatly increase remission rates with first drug selected through the proprietary combinatorial algorithm based on the understanding of Auto-Binding Cassette and Uridyl-Glucuronosyltransferase systems. In addition to the power of this algorithm, AMPLIS offers LuminusLive for an understanding of medications, their interactions and genetic influences in addition to a portal for virtual medication changes which can be analyzed in a matter of minutes. Co-existing morbidities can be efficiently treated while reducing risk to the patient for ADRs, Anti-cholinergic burden, Life style implications and genetic influences with up to the minute recommendations based on twice-daily scraping of over 6000 entries performed by Artificial Intelligence with respect to each tested genetic pathway and over 36,000 medications, herbals and OTC products along with current live-market pricing of each medication considered.

  • Agomelatine(Valdoxan®)
  • Amitriptyline (Elavil®)
  • Bupropion (Wellbutrin®)
  • Citalopram(Celexa®)
  • Clomipramine (Anafranil®)
  • Duloxetine (Cymbalta®)
  • Desvenlaxafine (Pristiq®)
  • Escitalopram (Lexapro®)
  • Fluoxetine (Prozac®)
  • Fluvoxamine (Luvox®)
  • Levomilnacipran (Fetzima®)
  • Mirtazapine (Remeron®)
  • Nortriptyline (Pamelor®)
  • Paroxetine (Paxil®)
  • Reboxetine (Edronax®)
  • Sertraline (Zoloft®)
  • Trazadone (Desyrel®)
  • Venlafaxine (Effexor®)
  • Vilazodone (Viibryd®)
  • Vortioxetine(Trintellix®)

  1. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci. 2015;13(2):150-6.
  2. Bousman, C. A., Müller, D. J., Ng, C. H., Byron, K., Berk, M., & Singh, A. B. (2016). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. Pharmacogenetics and genomics, 27(1), 1-6.

SSRI Antidepressants3

Drug Class Description:

Selective serotonin reuptake inhibitors (SSRIs) are prescribed to treat various psychiatric conditions, including depression, anxiety and personality disorders. SSRIs act by blocking the serotonin (5-HT) receptors in the brain. Suboptimal responses can delay the use of effective medications and remission of symptoms. Genetic differences can play an important role in determining patient responses.

  • Citalopram
  • Escitalopram
  • Fluoxetine
  • Fluvoxamine
  • Paroxetine
  • Sertraline
  • Vilazodone

3  Please visit http://www.pharmgkb.org for full list of pathways

SNRI Antidepressants3

Drug Class Description:

Serotonin and norepinephrine reuptake inhibitors (SNRIs) such as duloxetine, levomilnacipran and venlafaxine are primarily indicated for the treatment of major depressive disorder (MDD). Some SNRIs are also prescribed to treat anxiety disorders and neuropathic pain. SNRIs, like SSRIs, are second-generation antidepressants that are better tolerated than first-generation antidepressants such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).

  • Duloxetine
  • Levomilnacipran
  • Venlafaxine

3  Please visit http://www.pharmgkb.org for full list of pathways

TCA Antidepressants3

Drug Class Description:

Tricyclic antidepressants (TCAs) are prescribed to treat depression and various other psychiatric conditions. TCAs act by blocking the neuronal uptake of norepinephrine and serotonin; the binding of TCAs to cholinergic, alpha-adrenergic, serotonin and histamine receptors contributes to various side effects.

  • Amitriptyline
  • Clomipramine
  • Desipramine
  • Doxepin
  • Imipramine
  • Nortriptyline
  • Protriptyline
  • Trimipramine

3  Please visit http://www.pharmgkb.org for full list of pathways

Other Antidepressants3

Drug Class Description:

Other antidepressants that are used to treat depression and anxiety disorders include: Bupropion – a norepinephrine and dopamine reuptake inhibitor (NDRI) and a non-competitive antagonist of the nicotine receptors; Buspirone – an anti-anxiety medication unrelated to benzodiazepines; Mirtazapine – a commonly prescribed second-generation tetracyclic antidepressant that inhibits adrenergic alpha2-autoreceptors and serotonin 5-HT2 and 5-HT3 receptors; nefazodone – a phenylpiperazine antidepressant not related to SSRIs, TCAs and monoamine oxidase inhibitors, and blocks the serotonin 5-HT2 receptors; trazodone – a serotonin antagonist and a serotonin reuptake inhibitor (SARI) related to nefazodone; vortioxetine – a multimodal antidepressant that can be a useful alternative to serotonergic antidepressants for some patients who are partial responders or non-responders.

  • Bupropion
  • Buspirone
  • Mirtazapine
  • Nefazodone
  • Trazodone
  • Vortioxetine

3  Please visit http://www.pharmgkb.org for full list of pathways

Make Virtual Medication Changes and Plan Risk Reduction Strategies within Minutes with LuminusLIVE™